Relationship between reversible acetylcholinesterase inhibition and efficacy against soman lethality.
Carbamate pretreatment (45% inhibition, reversible), combined with therapy, protected rats from soman-induced lethality [The Pharmacologist 23, 224 (1981)]. The present study was done to see if less than 45% inhibition protects and to see if reversible acetylcholinesterase (AChE) inhibition and efficacy against soman lethality are correlated. At 30 min pre-soman, guinea pigs and rats received (im) either pyridostigmine (Py) or physostigmine (Ph) to inhibit whole blood AChE from 10 to 70%; at 1 min post-soman (sc), they received (im) atropine (16 mg/kg)/2-PAMCl (50 mg/kg) and mecamylamine (0.8 mg/kg)/atropine (16 mg/kg), respectively. Protective ratios (PRs) were computed and they ranged from 3.1 to 7.7 for guinea pigs and from 1.8 to 2.4 for rats. In guinea pigs the PRs for Py + therapy were roughly similar to those of Ph + therapy. In both species at 30 min after im injection of Py and Ph, a linear relationship was found between percentage of whole blood AChE inhibition and ln dosage of carbamate. Positive correlation (p less than 0.05) was found between the degree of reversible AChE inhibition by pretreatment, coupled with therapy, and efficacy against soman lethality. The present data indicate that inhibition levels as low as 10% may provide some protection.
D000110:Acetylcholinesterase / Q000097:blood; D000818:Animals; D001285:Atropine / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006168:Guinea Pigs; D008297:Male; D008464:Mecamylamine / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000037:antagonists & inhibitors*; D010830:Physostigmine / Q000627:therapeutic use; D011220:Pralidoxime Compounds / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D051381:Rats; D012999:Soman / Q000037:antagonists & inhibitors* / Q000506:poisoning
D002800:Cholinesterase Inhibitors; D009943:Organophosphorus Compounds; D011220:Pralidoxime Compounds; D008464:Mecamylamine; D001285:Atropine; D012999:Soman; D010830:Physostigmine; D000110:Acetylcholinesterase; D011729:Pyridostigmine Bromide; C028797:pralidoxime